Skip to content
10-Q

Quarterly Report

NIKA PHARMACEUTICALS, INC NIKA

0001826466-24-000068

← back to feed
Filed
May 28, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 24, 2024 1.02B sh
Short Term Debt Q1 2024 · Mar 31, 2024 $256.62K
Short Term Debt Q1 2024 · Dec 31, 2023 $101.75K
Cash And Equivalents Q1 2024 · Mar 31, 2024 $24.47K
Cash And Equivalents Q1 2024 · Dec 31, 2023 $19.6K
Current Liabilities Q1 2024 · Mar 31, 2024 $265.96K
Current Liabilities Q1 2024 · Dec 31, 2023 $101.75K
Total Liabilities Q1 2024 · Mar 31, 2024 $265.96K
Total Liabilities Q1 2024 · Dec 31, 2023 $101.75K
Current Assets Q1 2024 · Mar 31, 2024 $41.47K
Current Assets Q1 2024 · Dec 31, 2023 $19.6K
Total Assets Q1 2024 · Mar 31, 2024 $41.47K
Total Assets Q1 2024 · Dec 31, 2023 $19.6K
Shares Diluted Q1 2024 · Mar 31, 2023 876.09M sh
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$19.57K
Stockholders Equity Q1 2024 · Mar 31, 2023 −$36.89K
Stockholders Equity Q1 2024 · Dec 31, 2022 −$17.32K
Eps Diluted Q1 2024 · Mar 31, 2023 $0.00
Eps Basic Q1 2024 · Mar 31, 2023 $0.00
Sga Expense Q1 2024 · Mar 31, 2023 $19.57K
Net Income restated Q1 2024 · Mar 31, 2023 −$19.57K
Operating Income restated Q1 2024 · Mar 31, 2023 −$19.57K